Detalhe da pesquisa
1.
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation.
N Engl J Med
; 2024 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38767614
2.
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.
N Engl J Med
; 389(3): 205-214, 2023 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37272521
3.
Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.
N Engl J Med
; 389(14): 1263-1272, 2023 Oct 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37792612
4.
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis.
N Engl J Med
; 387(25): 2317-2330, 2022 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36546624
5.
Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials.
J Allergy Clin Immunol
; 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38431226
6.
Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma.
J Allergy Clin Immunol
; 2024 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38272375
7.
Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial.
J Am Acad Dermatol
; 90(6): 1190-1199, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38296199
8.
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 400(10356): 908-919, 2022 09 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36116481
9.
Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial.
Clin Infect Dis
; 75(1): e380-e388, 2022 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35219277
10.
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.
N Engl J Med
; 378(26): 2475-2485, 2018 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29782224
11.
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
N Engl J Med
; 378(26): 2486-2496, 2018 06 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29782217
12.
Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
Gastroenterology
; 158(1): 111-122.e10, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31593702
13.
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
J Am Acad Dermatol
; 82(2): 377-388, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31374300
14.
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
N Engl J Med
; 375(24): 2335-2348, 2016 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27690741
15.
Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis.
J Am Acad Dermatol
; 80(1): 158-167.e1, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30092324
16.
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Lancet
; 389(10086): 2287-2303, 2017 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28478972
17.
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
N Engl J Med
; 376(11): 1090-1, 2017 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28296614
18.
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma.
Respir Med
; 224: 107535, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38272376
19.
Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE Study.
J Allergy Clin Immunol Pract
; 12(4): 948-959, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38092225
20.
Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study.
Lancet Respir Med
; 12(1): 45-54, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37956679